Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    MEDI9929
Show Display Options
Rank Status Study
1 Completed A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects
Condition: Healthy
Interventions: Drug: MEDI9929;   Drug: Placebo
2 Completed A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
Condition: Asthma
Intervention: Drug: MEDI9929 (AMG 157)
3 Active, not recruiting Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
Condition: Asthma
Interventions: Drug: Placebo;   Drug: MEDI9929 - Low Dose IP;   Drug: MEDI9929 - Medium Dose IP;   Drug: MEDI9929 - High Dose IP
4 Not yet recruiting Effects of Anti-TSLP in Patients With Asthma
Condition: Asthma
Interventions: Drug: MEDI9929;   Drug: Placebo
5 Completed Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Biological: MEDI9929;   Biological: Placebo
6 Recruiting Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy
Conditions: Cat Allergy;   Cat Hypersensitivity
Interventions: Biological: AMG 157;   Biological: Cat Immunotherapy;   Biological: Cat Immunotherapy Placebo;   Biological: AMG 157 Placebo

Indicates status has not been verified in more than two years